Latent course of liver fibrosis in patients with chronic hepatitis B: comparative evaluation of noninvasive diagnostic methods (APRI, FIB-4 and FibroScan).
Authors
Mirzayeva Mehriniso Rizoyevna, Yodgorova Maqsad Shukhratovna
Share
Annotation
Liver fibrosis in chronic hepatitis B (CHB) often progresses latently, posing diagnostic challenges, particularly in asymptomatic patients. This study compares the efficacy of noninvasive diagnostic methods—APRI, FIB-4, and FibroScan—in detecting early-stage liver fibrosis among 250 CHB patients in a multicenter cohort from 2022 to 2025. APRI demonstrated a sensitivity of 72% and specificity of 68% (AUC 0.70, 95% CI: 0.65–0.75), while FIB-4 showed 78% sensitivity and 74% specificity (AUC 0.76, 95% CI: 0.71–0.81). FibroScan, as an elastography-based tool, achieved the highest accuracy with 85% sensitivity and 82% specificity (AUC 0.84, 95% CI: 0.80–0.88, p < 0.01 vs. APRI). Among 40% of patients with latent fibrosis (F1–F2 stages), FibroScan detected 92% of cases missed by APRI (p < 0.05). Objectives include evaluating diagnostic accuracy, assessing cost-effectiveness (FibroScan costs 20% more than APRI), and proposing guidelines for early detection. Findings suggest integrating FibroScan into routine CHB management to reduce undiagnosed fibrosis, prevalent in 30% of CHB cases globally.
Keywords
Authors
Mirzayeva Mehriniso Rizoyevna, Yodgorova Maqsad Shukhratovna
Share
References:
World Health Organization. WHO guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2024. Available from: https://www.who.int/publications/i/item/9789240090903
Chan A, Morey N, Brown A, et al. Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2024; S2468-1253(24):00437-0. doi:10.1016/S2468-1253(24)00437-0
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222. doi:10.1016/S0140-6736(20)30925-9
Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383-403. doi:10.1016/S2468-1253(18)30056-6
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398. doi:10.1016/j.jhep.2017.03.021
American Association for the Study of Liver Diseases. Hepatitis B guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis B virus. Hepatology. 2018;67(4):1560-1599. doi:10.1002/hep.29800
Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-526. doi:10.1053/jhep.2003.50346
Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-1325. doi:10.1002/hep.21178
Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29(12):1705-1713. doi:10.1016/j.ultrasmedbio.2003.07.001
Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48(5):835-847. doi:10.1016/j.jhep.2008.02.008
Li Y, Huang YS, Wang ZZ, et al. Systematic review with meta-analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2016;43(4):458-469. doi:10.1111/apt.13488
Xu XY, Kong H, Song RX, et al. The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy. PLoS One. 2014;9(6):e100182. doi:10.1371/journal.pone.0100182
Chen YP, Dai L, Wang JL, et al. Model consisting of ultrasonographic and simple blood indexes accurately identify compensated hepatitis B cirrhosis. J Gastroenterol Hepatol. 2020;35(8):1352-1359. doi:10.1111/jgh.15019
Lemoine M, Shimakawa Y, Nayagam S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut. 2016;65(8):1369-1376. doi:10.1136/gutjnl-2015-309260
Wang J, Malik N, Yin M, et al. Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis. World J Gastroenterol. 2017;23(5):859-868. doi:10.3748/wjg.v23.i5.85
Other articles of the issue
